肺部给药系统市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPHE100001256
  • Category : Medical Device
  • Status : Data Released
  • No. of Pages : 150
Buy Now

【研究报告】肺部给药系统市场规模预计将从2023年的497.1亿美元增至2031年的731.4亿美元;预计 2023 年至 2031 年市场复合年增长率为 4.9%。

市场洞察和分析师观点:

肺部药物输送系统用于将气雾剂直接输送至上皮细胞和呼吸道上皮通过吸入。这些系统包括吸入器和雾化器等设备,用于将药物输送到肺部以治疗患有呼吸道疾病的患者。肺部药物递送装置基于不同的递送机制并包含各种药物制剂。哮喘、慢性阻塞性肺疾病(COPD)、急性呼吸道感染、过敏性鼻炎和囊性纤维化是需要使用药物输送装置的主要呼吸系统疾病。呼吸系统疾病负担的增加和公司不断增加的战略举措有利于肺部给药系统市场的增长。肺部药物输送系统市场趋势包括吸入器技术的进步,这将有利于未来市场的增长。

增长动力:

不断在肺部药物输送系统市场运营的公司重点关注战略发展,例如协作、协议、伙伴关系和新产品发布。这些策略帮助他们提高销售额,扩大地理覆盖范围,并增强服务比现有客户群更广泛的能力。新产品的推出主要是为了提高安全性、用户友好的功能、更好的剂量功能等,以吸引大量的患者群体。以下是肺部药物输送系统市场的一些值得注意的发展:

2021 年 9 月,BreatheSuite Inc. 的 BreatheSuite 计量吸入器获得美国食品和药物管理局 (FDA) 的 510(K) 许可V1 设备可供处方药和非处方药使用。 BreatheSuite V1 通过自动准确地监测哮喘和慢性阻塞性肺病患者的吸入器依从性和技术并提供反馈,将现有的计量吸入器转变为智能吸入器。 2021 年 6 月,Glenmark Pharmaceuticals Ltd 推出了 Tiogiva,这是噻托溴铵干粉吸入器的生物等效版本,在英国治疗慢性阻塞性肺病。2021年4月,KINDEVA DRUG DELIVERY与Cambridge Healthcare Innovations Limited(CHI)合作,开发和商业化CHI的αeolus干粉吸入器(DPI)平台技术。2020年12月,创新数字健康AireHealth公司的连接雾化器已获得 510(k) 许可。该设备是一种便携式电子振动网雾化器。它设计用于雾化液体药物以供患者吸入。它以 VitalMed 品牌上市。 2020 年 9 月,葛兰素史克公司和 Innoviva, Inc. 获得 FDA 批准 Trelegy Ellipta,作为美国首个每日一次单一吸入器三联疗法,用于治疗美国 18 岁及以上哮喘和慢性阻塞性肺病患者.因此,公司为保持市场竞争力而进行的战略开发和产品发布数量不断增加,推动了肺部给药系统市场的增长。

战略见解

报告细分和范围:< br>
肺部给药系统市场分析是通过考虑以下细分市场进行的:产品、适应症、分销渠道、最终用户和地理位置。就产品而言,市场分为干粉吸入器、雾化器和定量吸入器。根据适应症,市场分为慢性阻塞性肺病、哮喘、囊性纤维化等。根据分销渠道,市场分为医院药房、零售药房和电子商务。根据最终用户,市场分为医院和诊所以及家庭护理。肺部给药系统市场报告的范围涵盖北美(美国、加拿大和墨西哥)、欧洲(法国、德国、英国、西班牙、意大利和欧洲其他地区)、亚太地区(中国、日本、印度) 、韩国、澳大利亚和亚太其他地区)、中东和非洲(沙特阿拉伯、南非、阿联酋以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)。

细分分析:

肺部药物输送系统市场按产品分为干粉吸入器、雾化器和定量吸入器。干粉吸入器细分市场在 2023 年占据了重要的市场份额。预计 2023 年至 2031 年期间将创下市场最高复合年增长率。

按产品划分的肺部给药系统市场份额 – 2023 年和 2031 年

从适应症来看,肺部给药系统市场分为慢性阻塞性肺疾病、哮喘、囊性纤维化等。慢性阻塞性肺疾病细分市场在 2023 年占据重要市场份额,预计 2023 年至 2031 年复合年增长率最高。

根据分销渠道,市场分为医院药房、零售药房和电子药房。 -商业。 2023 年,医院药房部门在肺部给药系统市场中占有重要份额。电子商务部门预计在 2023 年至 2031 年期间复合年增长率最高。

根据最终用户,肺部给药系统市场分为医院和诊所以及家庭护理。医院和诊所细分市场在 2023 年占据了重要的市场份额。预计家庭护理细分市场在 2023 年至 2031 年期间将实现更高的复合年增长率。

区域分析:

从地理上看,肺部给药系统市场分为北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2023年,北美占据了重要的市场份额。 2023年,美国占据该地区最大的市场份额。北美市场的增长归因于哮喘、慢性阻塞性肺病等呼吸系统疾病发病率的上升;老年人口不断增加;对诊断设备的需求不断增长;以及主要市场参与者的强大影响力。根据美国疾病控制与预防中心 (CDC) 的数据,2020 年,美国约有 5.0% 的成年人被诊断患有慢性阻塞性肺病 (COPD) 或慢性支气管炎。大约 2500 万人患有哮喘,1480 万人患有慢性阻塞性肺病 (COPD)。此外,加拿大护士协会估计加拿大约有 300 万人患有严重呼吸系统疾病之一,如慢性阻塞性肺病、囊性纤维化、哮喘和职业性肺病。

根据加拿大肺脏协会的数据,呼吸系统疾病此类疾病是导致住院治疗的第三大原因,加拿大大约五分之一的人患有严重的呼吸系统疾病,如哮喘、慢性阻塞性肺病、肺癌、肺结核、囊性纤维化和呼吸窘迫综合征。患有各种呼吸系统疾病的患者数量不断增加,推动了对创新有效的肺部药物输送系统(例如定量吸入器或雾化器)的需求。

行业发展和未来机遇:

肺部药物交付系统市场报告包括公司定位和集中度,以评估市场竞争对手的表现。根据公司新闻稿,以下是市场上主要参与者采取的一些举措:

2021 年 3 月,PARI Pharma GmbH 获得 LAMIRA 雾化器系统的授权,用于输送 Insmed 的药品 ARIKAYCE(阿米卡星脂质体)吸入悬浮液)在日本。 Insmed 于 2021 年 3 月获得日本厚生劳动省对 ARIKAYCE 的批准。 ARIKAYCE 在美国和欧洲获得早期批准后在该国获得批准。 2020 年 12 月,欧盟委员会在欧盟批准了阿斯利康的 Trixeo Aerosphere对于慢性阻塞性肺病。它用于治疗患有中度至重度慢性阻塞性肺病的成年患者。 Trixeo Aerosphere 是一种单吸入器、固定剂量三联复方,由富马酸福莫特罗、格隆溴铵、布地奈德和吸入皮质类固醇组成,通过加压计量吸入器输送。竞争格局和主要公司:

肺部给药系统市场预测可以帮助利益相关者规划他们的增长战略。阿斯利康、葛兰素史克、诺华、皇家飞利浦、勃林格殷格翰国际有限公司、西普拉公司、欧姆龙公司、PARI GmbH、Glenmark Pharmaceuticals 和 Gilbert Technologies 是市场上的知名参与者。这些公司专注于推出新的高科技产品、现有产品的进步以及地域扩张,以满足全球不断增长的消费者需求。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which segment is dominating the pulmonary drug delivery systems market?

The global pulmonary drug delivery systems market is segmented based on product, indication, distribution channel, and end user. The pulmonary drug delivery systems market, by product, is categorized into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment held a significant market share in 2023 and is anticipated to record the highest CAGR in the market during 2023–2031.

What was the estimated pulmonary drug delivery systems market size in 2023?

The pulmonary drug delivery systems market was valued at US$ 49.71 billion in 2023.

What are the growth estimates for the pulmonary drug delivery systems market till 2031?

The pulmonary drug delivery systems market is expected to be valued at US$ 73.14 billion in 2031.

Who are the major players in the pulmonary drug delivery systems market?

The pulmonary drug delivery systems market majorly consists of the players, including AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies.

What is pulmonary drug delivery systems?

Pulmonary drug delivery refers to the systems that target the delivery of aerosols directly to epithelial cells and respiratory epithelium through inhalation. These systems deliver the drug to the lungs to treat respiratory diseases. It is one of the most preferred drug delivery routes and a noninvasive technique with a large surface area of absorption and blood circulation.

What is the driving and restraining factors for the pulmonary drug delivery systems market?

The factors driving the growth of the pulmonary drug delivery systems market include the increasing burden of respiratory diseases and growing strategic initiatives by companies. However, regulatory issues associated with the approval of pulmonary drug delivery systems hampers the growth of the pulmonary drug delivery systems market.

The List of Companies - Pulmonary Drug Delivery Systems Market

  1. AstraZeneca
  2. GlaxoSmithKline Plc
  3. Novartis AG
  4. Koninklijke Philips NV
  5. Boehringer Ingelheim International GmbH
  6. Cipla Inc
  7. OMRON Corp.
  8. PARI GmbH
  9. Glenmark Pharmaceuticals
  10. Gilbert Technologies

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports